T1	Participants 181 291	patients with functional dyspepsia, supporting the use of prokinetic drugs for treatment of dyspeptic symptoms
T2	Participants 367 394	1298 patients were enrolled
T3	Participants 648 1113	Patients were selected on the basis of: a) occurrence in the last 4 weeks of at least 5/10 selected symptoms (anorexia, nausea, vomiting, upper abdominal pain, postprandial bloating, abdominal fullness, early satiety, belching, heartburn, regurgitation), severity of which should reach/exceed a total score of 8, as assessed by a specific scale ranging from 0 (absent) to 3 (severe); b) normal results of routine biochemical, ultrasound and endoscopic examinations.
